HIV Vaccine Regimen Demonstrates Modest Preventive Effect in Thailand Clinical Study

In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S. Army, the trial sponsor, announced today that the prime-boost investigational vaccine regimen was safe and 31 percent effective in preventing HIV infection.

“These new findings represent an important step forward in HIV vaccine research,” says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, which provided major funding and other support for the study. “For the first time, an investigational HIV vaccine has demonstrated some ability to prevent HIV infection among vaccinated individuals. Additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection, but certainly this is an encouraging advance for the HIV vaccine field.”

To learn more, read the full press release and Exit Disclaimer for more information about the Thai Phase III HIV vaccine trial.


  1. This is some of the best news we’ve had in quite a long time! I grew up in San Francisco and saw first hand the devastation that AIDS can do on a large scale. Let’s hope testing goes well and this becomes available soon.

  2. That’s great news. Keep up the good work guys – one day there will be a full cure. Hopefully around the same time as a cure for cancer.

  3. This is such great news! An exciting step forward with this crucial research.

  4. What great news! A bit of encouragement to spur the effort on.

Speak Your Mind


* Copy This Password *

* Type Or Paste Password Here *